‘Diseases Don’t Discriminate’: CISCRP Hopes To Improve Trial Diversity With Targeted Messaging

The Center for Information & Study on Clinical Research Participation partnered with drug makers to bring trial awareness to diverse communities and also to help along companies’ own diversity efforts.

• Source: Alamy

It’s easy for consumers to take the availability of drugs for granted when they’re picking up a prescription or getting an injection at the doctor’s office, but the process of making those drugs available through expensive and complex clinical development is hard, Center for Information & Study on Clinical Research Participation (CISCRP) senior director for marketing and outreach Joan Chambers explained in an interview. Increasing awareness of the clinical trial process and need for those trials to enroll a broad spectrum of participants is part of what CISCRP wanted to accomplish with its ongoing awareness campaign.

The CISCRP’s International Clinical Trial Outreach and Awareness Initiative started in November 2019 and consisted of an ad campaign over...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Diversity & Inclusion

Publisher’s Spotlight: The Winners Of The 2024 Citeline Awards

 

Congratulations to the winners of the 2024 Citeline Awards, held 8 May in Boston. 

Publisher’s Spotlight: The Citeline Awards Are Open For Entries!

 

Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees. 

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

 

Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.

Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership

 

Global crises and a tough funding environment mean biopharma leadership teams need to work hard to survive, let alone thrive. Industry executives shared their predictions and advice on strategy for 2024.

More from ESG

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

 

Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.

Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership

 

Global crises and a tough funding environment mean biopharma leadership teams need to work hard to survive, let alone thrive. Industry executives shared their predictions and advice on strategy for 2024.

Profile: MSD India Chief On DEI Values, Keytruda And 'Drinking From The Firehose'

 

MSD India managing director Rehan Khan shares with Scrip glimpses of his life and professional journey, including diversity, equity and inclusion values imbibed in his childhood, co-founding an early-stage venture fund, widening access to Keytruda to roughly “six times more patients” in the country and initiatives around HPV vaccination.